Adam Giermasz

Associate Professor of Medicine
Division of Hematology/Oncology, Hemophilia Treatment Center, University of California Davis
Sacramento, California, United States

Presentation(s):

• OC 02.3 - Etranacogene dezaparvovec hemophilia B gene therapy phase 2b trial final results: stable and durable FIX level expression over 5 years

  Saturday, June 22, 2024
  13:30 – 13:45 ICT

• OC 30.2 - Efficacy and safety of valoctocogene roxaparvovec 4 years after gene transfer in GENEr8-1

  Monday, June 24, 2024
  09:45 – 10:00 ICT